JP2021042159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021042159A5 JP2021042159A5 JP2019165017A JP2019165017A JP2021042159A5 JP 2021042159 A5 JP2021042159 A5 JP 2021042159A5 JP 2019165017 A JP2019165017 A JP 2019165017A JP 2019165017 A JP2019165017 A JP 2019165017A JP 2021042159 A5 JP2021042159 A5 JP 2021042159A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- active compound
- pharmaceutically active
- derivative
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000858 Cyclodextrin Polymers 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 10
- 235000019658 bitter taste Nutrition 0.000 claims 6
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- 229960002496 duloxetine hydrochloride Drugs 0.000 claims 3
- JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019165017A JP7390830B2 (ja) | 2019-09-11 | 2019-09-11 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2023197093A JP7857271B2 (ja) | 2019-09-11 | 2023-11-21 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230713A JP2026026340A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230714A JP2026026341A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230715A JP2026026342A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019165017A JP7390830B2 (ja) | 2019-09-11 | 2019-09-11 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197093A Division JP7857271B2 (ja) | 2019-09-11 | 2023-11-21 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021042159A JP2021042159A (ja) | 2021-03-18 |
| JP2021042159A5 true JP2021042159A5 (enExample) | 2022-09-15 |
| JP7390830B2 JP7390830B2 (ja) | 2023-12-04 |
Family
ID=74863742
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019165017A Active JP7390830B2 (ja) | 2019-09-11 | 2019-09-11 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2023197093A Active JP7857271B2 (ja) | 2019-09-11 | 2023-11-21 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230713A Pending JP2026026340A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230715A Pending JP2026026342A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230714A Pending JP2026026341A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197093A Active JP7857271B2 (ja) | 2019-09-11 | 2023-11-21 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230713A Pending JP2026026340A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230715A Pending JP2026026342A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
| JP2025230714A Pending JP2026026341A (ja) | 2019-09-11 | 2025-12-04 | 医薬活性化合物の苦味抑制剤及び苦味抑制方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (5) | JP7390830B2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230173533A (ko) * | 2022-06-17 | 2023-12-27 | 주식회사 코아팜바이오 | 신규한 구강용해산 조성물 |
| CN119564602A (zh) * | 2025-02-08 | 2025-03-07 | 江苏长泰药业股份有限公司 | 一种盐酸托莫西汀口服溶液的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU746887B2 (en) * | 1998-09-15 | 2002-05-02 | Eli Lilly And Company | Treatment of persistent pain |
| US6984632B1 (en) * | 1999-07-01 | 2006-01-10 | Italfarmaco S.P.A. | Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives |
| CA2451914A1 (en) * | 2001-08-08 | 2003-02-20 | John-Michael Sauer | Combination therapy for the treatment of neurological disorders |
| EP1904039A2 (en) * | 2005-06-20 | 2008-04-02 | Cadila Healthcare Ltd. | Controlled release dosage formulation of duloxetine |
| EP2583669A1 (en) * | 2007-10-10 | 2013-04-24 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
| CA2765635C (en) * | 2009-06-25 | 2016-09-06 | Wockhardt Research Centre | Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof |
| CN102579403B (zh) * | 2011-12-26 | 2013-08-21 | 天津市嵩锐医药科技有限公司 | 盐酸度洛西汀药物组合物 |
| US9855228B1 (en) * | 2016-12-14 | 2018-01-02 | Taho Pharmaceuticals Ltd. | Oral solution comprising atomoxetine hydrochloride and methods thereof |
| US11266658B2 (en) * | 2017-03-03 | 2022-03-08 | Ctc Bio, Inc. | Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration |
-
2019
- 2019-09-11 JP JP2019165017A patent/JP7390830B2/ja active Active
-
2023
- 2023-11-21 JP JP2023197093A patent/JP7857271B2/ja active Active
-
2025
- 2025-12-04 JP JP2025230713A patent/JP2026026340A/ja active Pending
- 2025-12-04 JP JP2025230715A patent/JP2026026342A/ja active Pending
- 2025-12-04 JP JP2025230714A patent/JP2026026341A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513467A5 (enExample) | ||
| CO2019005729A2 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos | |
| JP2017105763A5 (enExample) | ||
| JP2007302683A5 (enExample) | ||
| EP4293009A3 (en) | Fenfluramine compositions and methods of preparing the same | |
| NO20073928L (no) | Stabilt partikkelformig legemiddel med solifenacin eller salt av dette | |
| NZ597109A (en) | Tablet composition having favorable dissolution property useful as an anticoagulant | |
| WO2007123955A3 (en) | Stable hydroalcoholic oral spray formulations and methods | |
| JP2010513478A5 (enExample) | ||
| NO20062619L (no) | Doseringssystem med kontrollert frigivning for nasale anvendelser | |
| JP2014129360A5 (enExample) | ||
| JP2008044957A (ja) | 抗真菌マニキュア組成物 | |
| HK1222297A1 (zh) | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 | |
| JP2010090168A5 (enExample) | ||
| JP2012092123A5 (enExample) | ||
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| HRP20251463T1 (hr) | Farmaceutska kombinacija koja sadrži ponesimod i njegova upotreba u liječenju multiple skleroze | |
| EA201990501A1 (ru) | Фармацевтическая композиция | |
| NO20062051L (no) | Farmasoytisk virkestoffinneholdende formulering med belegg | |
| JP2015514739A5 (enExample) | ||
| SA521422467B1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| JP2019151627A5 (enExample) | ||
| NO20083759L (no) | Doserings aerosoler for administrering av farmasoytiske preparater | |
| JP2025507472A5 (enExample) | ||
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica |